相关实验视频

Updated: Jan 13, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

1,1-二氧乙增加了胰岛素敏感性,并改善肥胖和脂质不良症在食高脂肪饮食的小鼠

Thang Nguyen Huu¹, Hien Duong Thanh², Min-Kyu Kim³

¹Department of Biochemistry, Department of Biomedical Sciences, Research Center for Aging and Geriatrics, Research Institute of Medical Sciences, Chonnam National University Medical School, Gwangju, Republic of Korea.

npj metabolic health and disease

|January 7, 2026

概括

在细胞和小鼠模型中,葡萄酒中的一种化合物1,1-二氧乙 (1,1-DEE) 已被发现可以改善胰岛素敏感性,并对抗肥胖和糖尿病. 这种调味剂在代谢疾病干预方面表现有前途.

科学领域:

生物化学生物化学
代谢研究的研究.
分子生物学分子生物学

背景情况:

酒精饮料对健康产生影响,与肥胖,糖尿病和心血管问题有关.
1,1-二氧化乙 (1,1-DEE) 是葡萄酒调味剂化合物,在老化过程中由花酵母产生的.
了解1,1-DEE对健康的影响对于代谢疾病研究至关重要.

研究的目的:

为了研究1,1-二氧化乙 (1,1-DEE) 的生物活性功能.
评估1,1-DEE在肥胖和糖尿病等代谢障碍中的潜在治疗作用.
阐明1,1-DEE对胰岛素信号传递和新陈代谢影响的分子机制.

主要方法:

利用培养细胞系 (C2C12神经质) 和高脂肪饮食 (HFD) 的小鼠模型.
使用凝移动性转移试验和气体染色体质谱法确定了1,1-DEE.
分析了PTEN氧化,线粒体反应性氧物种的产生,Akt信号,并进行了转录组分析.

主要成果:

1,1-DEE诱导了10号染色体 (PTEN) 上被删除的酸酶和张素同类物的可逆氧化,与1,2-DEE不同.
1,1-DEE增强了线粒体的活性氧物种的产生,导致PTEN氧化和Akt信号激活.
口服1,1-DEE给药改善了HFD小鼠的葡萄糖耐受性,胰岛素耐药性,体重和肝脏脂质不良.

结论:

1,1-DEE显示出作为代谢疾病治疗剂的显著潜力.
该化合物减轻了胰岛素抵抗和相关的代谢并发症.
对1,1-DEE的进一步研究可能会导致针对肥胖,糖尿病和脂质失调的新型干预措施.

更多相关视频

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...